To confirm the MS identification of the protein, we incubated the proteomic maps obtained from the tumor cells of 10 anti-ENO1 Ab+ (patients 22, 23, 24, 25, 26, 27, 29, 31, 32, 33) and 4 anti-ENO1 Ab- patients (patients 28, 30, 34, 35) with a commercially available anti-ENO1 polyclonal Ab. This evidence concerns the gene ENO1 and neoplasm.